Conclusions: Our meta-analysis suggests that administration route may affect the renal safety of contrast agents. Specifically, iodixanol may be a better choice for patients in the interventional cardiology setting.
PMID: 22252847 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)